Hualan Biological Engineering: Net profit rose 17.2% year-over-year on strong blood product sales and higher R&D investment

About this update from Hualan Biological Engineering Inc. Class A

Revenue and net profit grew 8.8% and 17.2% year-over-year, driven by strong blood product sales and a surge in vaccine revenue. R&D investment rose, with several innovative drugs advancing in clinical trials. A cash dividend of ¥5 per 10 shares was proposed, exceeding net profit for the period.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Hualan Biological Engineering Inc. Class A